Drug assessment at a glance: A26-25[1]

Mepolizumab (COPD)

25 August 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-25. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Adults with uncontrolled COPD characterized by raised blood eosinophils on a combination of an ICS, a LABA and a LAMA
Intervention	mepolizumab as an add-on maintenance treatment
Comparator	Individualized treatment from a choice of ▪ LABA and LAMA and ICS and dupilumab ▪ LABA and LAMA and ICS and roflumilast
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: no advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No relevant study was identified.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Mepolizumab (COPD); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 20.08.2026]. URL: https://doi.org/10.60584/A26-25.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Mepolizumab (Neues Anwendungsgebiet: COPD) [online]. 2026 [Accessed: 20.08.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1323/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-25.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de